Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to establish a model for the evaluation of drug targets using postural measures to induce changes in lung water concentration as assessed by MRI. A reduction in the magnitude and rate of water transudation with postural changes in patients with congestive heart failure (CHF) could provide a model for the evaluation of various classes of molecules for target validation and for dose selection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Volunteer | Other | Healthy Volunteer cohort |
|
| Heart Failure | Other | Heart Failure cohort |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MRI | Procedure | MRI of lungs to measure lung water content before and after passive leg raising (PLR) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lung water distribution as measured by MRI | MRI test | Visit 1 and Visit 2 will be approximately 1 week apart |
| Lung water concentration as measured by MRI | MRI test | Visit 1 and Visit 2 will be approximately 1 week apart |
| Measure | Description | Time Frame |
|---|---|---|
| Between patient variability in lung water concentration as measured by MRI at 2 independent visits | MRI test | Visit 1 and Visit 2 will be approximately 1 week apart |
| Within patient variability in lung water concentration as measured by MRI at 2 independent visits |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | London | W12 0HS | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D011654 | Pulmonary Edema |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
MRI test |
| Visit 1 and Visit 2 will be approximately 1 week apart |